Wockhardt Limited is a global pharmaceutical and biotechnology company engaged in the research, development, manufacturing, and commercialization of branded pharmaceuticals, generic medicines, biologics, vaccines, and active pharmaceutical ingredients. Founded in 1960, the company has established operations across India, the United States, the United Kingdom, Ireland, and several emerging markets. Wockhardt has developed expertise in antibiotics, critical care, biotechnology, diabetes, vaccines, and novel anti-infective therapies. The company is particularly recognized for its investment in new antibiotic discovery and research targeting antimicrobial resistance, one of the world’s most pressing healthcare challenges. Its manufacturing facilities comply with stringent international regulatory standards, supporting exports to numerous regulated markets. Through continuous scientific innovation, strategic research initiatives, and high-quality manufacturing, Wockhardt remains committed to addressing unmet medical needs while strengthening its position as a research-driven global pharmaceutical company.
NSE: WOCKPHARMA | BSE: 532300
Mumbai, Maharashtra, India
~10,000 employees
